Cancer immunotherapy comes of age and looks for maturity

Nat Commun. 2020 Jul 3;11(1):3325. doi: 10.1038/s41467-020-17140-5.

Abstract

As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / immunology
  • CTLA-4 Antigen / metabolism
  • Gene Editing / methods*
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Oncolytic Virotherapy / methods*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • Programmed Cell Death 1 Receptor / metabolism
  • Protein Engineering / methods*
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / metabolism

Substances

  • Antibodies, Monoclonal
  • CTLA-4 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptor, ErbB-2